Ayami Isonishi1, Charles L Bennett2, Barbara Plaimauer3, Friedrich Scheiflinger3, Masanori Matsumoto1, Yoshihiro Fujimura1. 1. Department of Blood Transfusion Medicine, Nara Medical University, Kashihara City, Japan. 2. South Carolina Center of Economic Excellence for Medication Safety and Efficacy, the Southern Network on Adverse Reactions (SONAR), the South Carolina College of Pharmacy, and the WJB Dorn Veterans Administration Hospital, Columbia, South Carolina. 3. Department of Discovery Research and Technical Assessment, Baxter Bioscience, Vienna, Austria.
Abstract
BACKGROUND: Plasma exchange (PE) is the first-line treatment for primary acquired thrombotic thrombocytopenic purpura (aTTP) with severe deficiency of ADAMTS13 activity (ADAMTS13:AC). Some patients are poor responders to PE, raising concern over multiple pathogenetic pathways. STUDY DESIGN AND METHODS: Based on 52 aTTP patients in our national cohort study, we monitored plasma levels of ADAMTS13, clinical and laboratory findings, and outcomes. In a representative poor responder to PE, we examined an ADAMTS13 inhibitor (ADAMTS13:INH) complex in plasma milieu, by means of a large-pore isoelectric focusing (IEF) analysis. RESULTS: Of 52 aTTP patients, 20 were good responders and 32 were poor responders. In the latter group, plasma ADAMTS13:AC levels never increased to more than 10% of normal during 14 days after PE initiation. Mean (±SD) plasma ADAMTS13:INH titers (Bethesda unit/mL) were 5.7 (±4.5) before PE, but decreased to 1.4 (±0.8) on the fourth PE day and then remarkably increased to 14.8 (±10.0) on the 10th PE day, termed "inhibitor boosting," and then slowly decreased to undetectable level over 1 month. On admission, none of the routinely available clinical and laboratory markers differentiated these two groups. However, elevated pre-PE levels of ADAMTS13:INH were correlated with a poor response. We visualized an ADAMTS13:INH (immunoglobulin G) complex in a patient plasma by an IEF analysis and found proteolytic fragment of ADAMTS13 antigen by a two-dimensional IEF and sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. CONCLUSION: Findings from this cohort of aTTP patients demonstrated that inhibitor boosting often occurs in aTTP patients in Japan. Poor responders could be predicted by elevated pre-PE ADAMTS13:INH levels on admission, but not by routinely collected clinical or laboratory data.
BACKGROUND: Plasma exchange (PE) is the first-line treatment for primary acquired thrombotic thrombocytopenic purpura (aTTP) with severe deficiency of ADAMTS13 activity (ADAMTS13:AC). Some patients are poor responders to PE, raising concern over multiple pathogenetic pathways. STUDY DESIGN AND METHODS: Based on 52 aTTPpatients in our national cohort study, we monitored plasma levels of ADAMTS13, clinical and laboratory findings, and outcomes. In a representative poor responder to PE, we examined an ADAMTS13 inhibitor (ADAMTS13:INH) complex in plasma milieu, by means of a large-pore isoelectric focusing (IEF) analysis. RESULTS: Of 52 aTTPpatients, 20 were good responders and 32 were poor responders. In the latter group, plasma ADAMTS13:AC levels never increased to more than 10% of normal during 14 days after PE initiation. Mean (±SD) plasma ADAMTS13:INH titers (Bethesda unit/mL) were 5.7 (±4.5) before PE, but decreased to 1.4 (±0.8) on the fourth PE day and then remarkably increased to 14.8 (±10.0) on the 10th PE day, termed "inhibitor boosting," and then slowly decreased to undetectable level over 1 month. On admission, none of the routinely available clinical and laboratory markers differentiated these two groups. However, elevated pre-PE levels of ADAMTS13:INH were correlated with a poor response. We visualized an ADAMTS13:INH (immunoglobulin G) complex in a patient plasma by an IEF analysis and found proteolytic fragment of ADAMTS13 antigen by a two-dimensional IEF and sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. CONCLUSION: Findings from this cohort of aTTPpatients demonstrated that inhibitor boosting often occurs in aTTPpatients in Japan. Poor responders could be predicted by elevated pre-PE ADAMTS13:INH levels on admission, but not by routinely collected clinical or laboratory data.
Authors: Martina Böhm; Christoph Betz; Wolfgang Miesbach; Manuela Krause; Charis von Auer; Helmut Geiger; Inge Scharrer Journal: Br J Haematol Date: 2005-06 Impact factor: 6.998
Authors: Silvia Ferrari; Kristina Palavra; Bernadette Gruber; Johanna A Kremer Hovinga; Paul Knöbl; Claudine Caron; Caroline Cromwell; Louis Aledort; Barbara Plaimauer; Peter L Turecek; Hanspeter Rottensteiner; Friedrich Scheiflinger Journal: Haematologica Date: 2013-11-15 Impact factor: 9.941
Authors: Johanna A Kremer Hovinga; Sara K Vesely; Deirdra R Terrell; Bernhard Lämmle; James N George Journal: Blood Date: 2009-12-23 Impact factor: 22.113
Authors: G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai Journal: Nature Date: 2001-10-04 Impact factor: 49.962
Authors: Linus A Völker; Jessica Kaufeld; Wolfgang Miesbach; Sebastian Brähler; Martin Reinhardt; Lucas Kühne; Anja Mühlfeld; Adrian Schreiber; Jens Gaedeke; Markus Tölle; Wolfram J Jabs; Fedai Özcan; Silke Markau; Matthias Girndt; Frederic Bauer; Timm H Westhoff; Helmut Felten; Martin Hausberg; Marcus Brand; Jens Gerth; Markus Bieringer; Martin Bommer; Stefan Zschiedrich; Johanna Schneider; Saban Elitok; Alexander Gawlik; Anja Gäckler; Andreas Kribben; Vedat Schwenger; Ulf Schoenermarck; Maximilian Roeder; Jörg Radermacher; Jörn Bramstedt; Anke Morgner; Regina Herbst; Ana Harth; Sebastian A Potthoff; Charis von Auer; Ralph Wendt; Hildegard Christ; Paul T Brinkkoetter; Jan Menne Journal: Blood Adv Date: 2020-07-14